Structure Therapeutics (GPCR) Enterprise Value (2023 - 2026)

Structure Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$2.6 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 70.55% year-over-year to -$2.6 billion; the TTM figure through Mar 2026 stood at -$2.6 billion (down 70.55% YoY), while the FY2025 annual figure was -$1.4 billion, up 9.01% from the prior year.
• Enterprise Value for Q1 2026 stood at -$2.6 billion, down from -$1.4 billion in the prior quarter.
• The five-year high for Enterprise Value was -$90.8 million in Q4 2022, with the low at -$2.6 billion in Q1 2026.
• The 5-year median for Enterprise Value is -$850.9 million (2024), against an average of -$948.3 million.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value slumped 414.44% in 2023, then increased 15.17% in 2025.
• Structure Therapeutics' Enterprise Value stood at -$90.8 million in 2022, then plunged by 414.44% to -$467.3 million in 2023, then slumped by 240.1% to -$1.6 billion in 2024, then increased by 9.01% to -$1.4 billion in 2025, then tumbled by 79.45% to -$2.6 billion in 2026.
• Business Quant data shows GPCR's Enterprise Value at -$2.6 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.5 billion in Q3 2025.